Skip to main content

Cerebral organoids: emerging ex vivo humanoid models of glioblastoma


Glioblastoma is an aggressive form of brain cancer that has seen only marginal improvements in its bleak survival outlook of 12–15 months over the last forty years. There is therefore an urgent need for the development of advanced drug screening platforms and systems that can better recapitulate glioblastoma’s infiltrative biology, a process largely responsible for its relentless propensity for recurrence and progression. Recent advances in stem cell biology have allowed the generation of artificial tridimensional brain-like tissue termed cerebral organoids. In addition to their potential to model brain development, these reagents are providing much needed synthetic humanoid scaffolds to model glioblastoma’s infiltrative capacity in a faithful and scalable manner. Here, we highlight and review the early breakthroughs in this growing field and discuss its potential future role for glioblastoma research.


A disease with a dismal prognosis

Glioblastoma multiforme (GBM) is a malignant primary brain tumor with a dismal 5-year survival rate of 5% and median survival of just 14 months [1]. Developments of effective treatments are challenged by GBM’s extensive cellular heterogeneity and its ability to infiltrate into surrounding brain tissue, making complete surgical resection infeasible [2]. The majority of GBM tumors recur, partly hypothesized to be due to the presence of a chemo-resistant stem-cell-like population that repopulates the tumor following therapy [3, 4]. Despite numerous drugs reaching clinical trials, the standard of care for GBM treatment has remained largely unchanged for almost two decades [5]. As such, there has been significant interest in refining and expanding laboratory models of GBM in an effort to better recapitulate its true biology, and in turn, help identify new and more effective therapies. Emerging models that combine synthetic tridimensional human neural cultures, known as cerebral organoids, with genetically tagged glioma stem cells have provided new tools for scientists to recapitulate the cellular and molecular heterogeneity of GBM. This includes both its ability to interact and infiltrate within normal brain tissue structures providing an exciting emerging model to study this deadly disease. Here, we compare and contrast this model with traditional systems and explore its complementary value in GBM research and discovery.

Traditional models of GBM

Primary GBM cell cultures have been crucial in understanding the biology of this disease by providing a widespread and accessible in vitro model. Following the successful isolation and characterization of glioblastoma stem cells (GSCs), that promote cancer progression and recurrence [6, 7], this in vitro system has offered significant insight into fundamental mechanisms of cellular drivers of GBM. However, these culture systems have come with limitations and compromise as they were not designed to capture complex three-dimensional aspects of GBM’s anatomical architecture, their interactions with native non-neoplastic tissue structures or its characteristic infiltrative behavior [8]. Recent research has also highlighted discrepancies observed when these systems are leveraged for drug discovery, with discordances in the efficacies of drugs in experimental and clinical settings [9]. Also absent from these systems are the reciprocal interactions between the tumor and healthy neural tissue. These interactions, such as the recently demonstrated electrical and synaptic integration of gliomas into surrounding neural tissue, have been shown to be especially relevant to the growth and progression of GBM [10,11,12]. These studies further highlight the need for models that incorporate the well-established role of the tumor microenvironment to allow research into escape mechanisms of GBM through invasion and host interactions.

Animal models have provided some solutions to the limitations of these in vitro cultures by providing a more holistic system for dissecting GBM molecular and cellular biology by incorporating tumor-host interactions [13]. Of these models, genetically engineered mouse models have been particularly useful in understanding GBM but are limited by substantial differences between human and mouse brains [14]. Furthermore, results from these models unfortunately have a history of being imperfect predictors of treatment outcomes in human clinical trials [15,16,17]. Moreover, recent studies using patient-derived xenograft (PDX) models showing a tendency for human-derived GSCs to undergo murine-specific changes, that diverge from human tumor biology, have also challenged these systems and potentially explain challenges in translating discoveries from that model to the clinic [18]. Along with genetically engineered mouse models, these PDX models also suffer from high costs and an incompatibility with medium to high-throughput drug screens. These limitations highlight the need for complementary tools that can serve as scalable and faithful models of human GBM biology including an ability to potentially capture the critical tumor-host interactions central to this disease.

Main Body

Early ex-vivo models of GBM and interactions with other cell types

Initial efforts to improve ex vivo modelling of GBM focused on examining the role of extracellular matrix components in cancer growth dynamics [19] and were successful in increasing the longevity and size of three dimensional GSC populations by embedding them in Matrigel [20]. These larger cell aggregates could be cultured for months and generated hypoxic niches that were enriched in stem like-cells that were radioresistant [20]. More recent efforts have also optimized a fast and efficient protocol for generating tumor “organoids” out of small primary tumor pieces that can be grown and stored in catalogued biobanks, whilst preserving the genetic profile and cellular heterogeneity of the original tumor [21]. Together these provide more complex models to study intra-tumoral heterogeneity of GBM in human exclusive cell systems. Alternatively, the development of scalable models that incorporate non-neoplastic cell-based compartments was addressed initially by efforts that co-cultured engineered neural tissue from embryonic stem cells with GSC spheres [22]. Even though early neuronal tissue did not provide the cellular heterogeneity present in the adult brain, this study was important as being the first to show that GSCs had the ability to interact with other human cell types in vitro. The issue of cellular heterogeneity was addressed in a recent study [23] that optimized a three-dimensional brain microphysiological cell protocol that could generate mature neurons and glial cells [24]. Plummer and colleagues added GSCs on a layer of neural precursor cells with the resulting hybrid spheres containing growing tumor cells, but critically did not show the characteristic invasive pattern of clinical GBM [23]. It is possible that the perturbed developmental programming of neural precursors, due to the addition of GSCs, resulted in a microenvironment that did not mimic the one present in the adult brain.

Cerebral organoids as an emerging model system

Cerebral Organoids (COs) are one of the most promising recent developments which attempt to provide an accurate microenvironment into which GSCs can infiltrate. These represent complex 3D cell aggregates derived from human pluripotent stem cells (hPSCs) which undergo neural differentiation and self-organize to form layered structures that resemble the developing human brain. COs have recently emerged as a model system for studying CNS disease within a human genetic background, as they appear to better recapitulate the cell diversity of the human cerebral cortex, including populations of neural progenitor cells, astrocyte precursor cells, oligodendrocyte precursor cells, excitatory neurons, inhibitory neurons and retinal cells [25, 26]. With remarkable structural similarities to the human brain, COs can also exhibit characteristics of cortical tissue architecture such as cell-type specific layering [27], and even cortical folding [28]. Recent efforts have also generated choroid-plexus-like organoids with a selective barrier resembling that of the blood–brain barrier. In addition to the ability to model production of cerebrospinal fluid, these organoids potentially allow for scalable assessment of a candidate drugs’ ability to cross the blood–brain barrier [29]. COs have been used to model brain development as well as a variety of diseases including microcephaly, lissencephaly, autism spectrum disorder, and even neurodegenerative disorders such as Alzheimer’s [30].

With the emergence of research pointing to GSCs being successfully used in more complex, fusion based culture protocols, recent studies have used human cerebral organoids as a model system to study GBM growth in a tridimensional human brain-like environment. These efforts can be broadly divided into two categories based on the method of inducing tumor formation in organoids. One is the use of genetically engineered organoid models, which are well suited for understanding genetic mechanisms of GBM induction within the 3D environment of healthy tissue that is present during in vivo tumorigenesis [31, 32]. The second relies on the introduction of patient derived GSCs into organoids, which is particularly well suited for understanding clinical characteristics following initial tumor formation. Due to the central role of GSCs as the cell type that drives tumor progression and recurrence [33], these efforts have focused on introducing GSCs into COs, either as single cells [34,35,36,37] or as GSC spheres [38]. Characteristic results of the latter method, which is utilized in our laboratory, are presented in Fig. 1.

Fig. 1
figure 1

Illustative example of how cerebral organoids are generated and their use for modeling GBM infiltration. a Typical developmental outline of cerebral organoid formation across time (i–iv) and validation with neuronal markers using histology (v) and immunofluorescence (vi) at 6 weeks to highlight formation of spatially organized brain-like tissue. Markers shown in immunofluorescence include SOX2 (primitive neuroepithelial progenitor cells), DCX (early neurons) and DAPI as a nuclear stain. b Characteristic epifluorescence image (i) of a fused GBM-organoid culture system through co-culturing of cerebral organoids with GFP-tagged GSCs. In (ii) immunofluorescence indicates the level of infiltration of GBM into neuronal tissue. In (ii), GFAP is used as a surrogate marker of the infiltrating GBM cells as it is not typically expressed in high levels in cerebral organoids at this timepoint (non-fused organoid in indent)

Co-culturing systems of GBM and cerebral organoids

After initial indications of the possibility for organoids being receptive to fusion [39], da Silva and colleagues introduced GSCs into cerebral organoids to model GBM [38]. They observed GSC spheroids consistently fusing, becoming incorporated within and exhibiting more infiltration in organoids when compared to fusions with neural progenitor spheroids. Additionally, immunofluorescence staining validated infiltration markers of GBM in this ex vivo model [38], despite using human-derived GSC spheroids and mouse-derived cerebral organoids. Given the differences in human and mouse brain structures [40], this co-culture system was not further used aside from being a proof-of-principle for future improvements. Subsequently, several other groups utilized the fusion approach as an ex vivo model of GBM [32, 34,35,36,37] and drug screening [31, 36].

A more recent study used stable lines of GFP tagged GSCs and co-cultured them with cerebral organoids to generate what authors called the “glioma cerebral organoid (GLICO)” model [36]. This system was observed to recapitulate features of human GBM behavior, namely the infiltration into normal brain tissue and the presence of 3D interconnecting tumor microtubes that were previously reported to serve as a key mechanism of tumor cell communication and resistance [41]. GLICOs were also able to maintain certain molecular signaling networks found in the actual tumors derived from patients, such as amplified epidermal growth factor receptor (EGFR) expression. Importantly, Linkous and colleagues observed differential sensitivity to chemotherapeutic agents in 2D GSC cell lines compared to GLICOs [36]. The latter presented a response more closely related to clinical observations, thereby making a case for the CO model’s ability to more closely recapitulate the true biology of GBM. Interestingly, this successful tumor cell invasion in the fusion model identified differentially expressed genes during this process [35]. Quantification of invasion from different GSC lines supported the capability of the fusion model to reproduce the clinical invasiveness properties of the original parent tumors. To next examine changes in gene expression of tumor cells during invasion, GSCs were co-cultured with cells from dissociated organoids and analyzed using single-cell RNA sequencing. These studies showed an upregulation of model-validating processes with invasion-related genes, as well as ligand-receptor pairs between interacting tumor and normal cells. These experiments, and the datasets generated, may also offer new insights, key molecular participants and targets for tumor invasion. However, it is important to note that these experiments didn’t faithfully recapitulate GBM behavior since the interaction between tumor and normal cell populations was brief and not in the context of brain tissue infiltration.

A similar ex vivo approach was used in another study that explored the diverse cell type composition of GBM tumors [34]. This study focused on a neuro-developmental cell type called outer radial glia that are believed to be reactivated in GBM and contribute to its heterogeneity. Similar to the developmental cell type, the outer radial glia-like tumor cells also express the cell surface marker PTPRZ1. To better understand the tumorigenic properties of these cells in the context of a human tissue microenvironment, Bhaduri and colleagues transplanted PTPRZ1 +/GFP + cells from primary tumors into cerebral organoids [34]. This led to invasion and expansion of the recipient organoids. The tumor cell population that was isolated from the fused culture was found to be composed primarily of neurons and astrocytes, which resembles the heterogenous composition of the initial primary tumor. The results of this study emphasize the strength of the fusion model in recapitulating the nature of GBM, specifically in terms of tumor cell type composition. This could be potentially due to successful mimicking of the tumor microenvironment forming between the fused cell populations.

Lastly, a recently published study compared different GBM models and their ability to reproduce cellular states found in primary tumors by single-cell RNA sequencing profiles sourced from four models: glioma spheres, tumor organoids, orthotopic PDXs, and GLICOs [37]. These results indicated that the composition of primary tumor cellular states was most similar to the one found in GLICOs. Moreover, the single cell signatures of GLICOs contained a greater diversity of cell types that were also found in primary tumors. Further analysis of their transcriptomic data showed that expression of Notch pathway members and GBM invasion genes was upregulated in a greater number of cells in GLICOs compared to other models, and the expression of certain Notch ligands was also increased in non-tumor cells of the GLICO. The dependency of these profiles on the presence of the organoid compartment in the model was further supported when GSCs derived from GLICOs were isolated and grown in 2D culture. Indeed, single-cell RNA sequencing of these cells revealed that they more closely resembled glioma spheres than primary tumors. These results not only underscore the critical interaction between tumor and normal cells for reproducing cellular states in GBM modelling, but also highlight the need for a more neuroanatomically accurate human microenvironment, which currently can only be achieved through the leveraging of cerebral organoids.

Genetically engineered organoid models of GBM

As an alternative to using patient-derived tumor cells, some groups have opted to model GBM in cerebral organoids by using genetic manipulations to induce tumorigenesis [31, 32]. This mirrors the commonly used approach of modeling GBM in genetically engineered mouse models and is well suited for studying early genetic events leading to tumor formation of human gliomas. One such study utilized CRISPR/Cas9 to simultaneously disrupt the tumor suppressor TP53 and insert the oncogene HRasG12V by homologous recombination [32]. Although the HRasG12V mutation itself is not a common feature of GBM, through this manipulation the authors were able to experimentally simulate Ras pathway overactivation, a common molecular feature of GBM biology [42]. As a proof of principle, this study demonstrated the ability to generate bona fide tumors that were highly invasive and proliferative. Transcriptomic profiles of the organoid-derived tumor cells were compared to established GBM subtypes and were found to resemble the mesenchymal subtype [43], further adding validity to the capability of this system to mimic clinically aggressive GBM subtypes. The study [32] also demonstrated that these organoid-derived tumor cells were serially transplantable between organoids and were lethal when introduced to immunocompromised mice, where they exhibited the morphological and angiogenic qualities of tumors observed in vivo. This study served as an important proof-of-concept report for the generation of genetically engineered organoid models of GBM. While the authors only carried out one genetic manipulation, this technique has the potential to be applied to the full range of mutations and molecular alterations clinically observed in GBM.

Other examples of this approach include efforts by Bian et al. which combined transposon-mediated insertion of oncogenes with CRISPR-Cas9-mediated mutagenesis of tumor suppressor genes [31]. Using this approach, 18 single gene mutations/amplifications and 15 common mutation/amplification combinations were generated. From these, the authors identified 4 that were capable of generating highly invasive tumors that overgrew into the surrounding organoid. In addition to high expression of invasion-related genes in the formed tumors, the authors identified transcriptional changes reflective of epithelial-to-mesenchymal transition. They also demonstrated that tumor growth could be attenuated by targeted drug treatment in some of the mutation/amplification combinations. Finally, they showcased the suitability of their system for use in large-scale drug screening by modifying the tumor cells to express firefly luciferase. The resulting luciferase activity could then be used to easily monitor tumor size when comparing the efficiency of various compounds on altering GBM growth dynamics.


Challenges and future directions

While organoid models have already begun addressing many of the long-standing limitations of existing GBM culture systems, they are not without challenges and limitations. High inter-organoid variability in both morphology and tissue identity remains a significant issue for CO-based disease models [27, 30]. Ongoing improvements in this area include growing organoids on microfilament scaffolds to maximize surface area that is thought to promote more uniform neuroectoderm formation and suppress unwanted mesoderm elements [27]. Further refinements include utilizing engineered extracellular matrix (ECM)-like materials to improve consistency [44]. These engineered materials have the potential to greatly improve inter-batch variability compared to currently used methods, which typically utilize Matrigel as an ECM scaffold [44]. Other strategies that are gaining support to promote more consistent and high throughput organoid generation include the use of microwells for uniform embryoid body formation [45] and more well-defined differentiation protocols that can reproducibly generate organoids containing brain-region-specific cell types [26, 46, 47]. Others have engineered miniaturized spinning bioreactors that allow for better availability of differentiation cues to the 3D culture and, as a result, more advanced maturation of neuronal subtypes [26]. Increasing consistency of cerebral organoids and their ability to mimic different brain regions is expected to improve the accuracy and reproducibility of CO-based models of GBM. As these protocols evolve and stabilize to their most reliable and robust versions, acquiring a consensus and widespread use across the scientific community, they will likely also provide further and refined insights about the molecular machinery responsible for GBM’s relentless invasiveness and growth potential. In addition, CO-based models of GBM have lacked development of vasculature, which plays an important role in GBM progression by providing additional migratory tracks for GBM cells to use in infiltrating into surrounding tissue [48]. The perivascular niche also plays an important role in GSC maintenance [49]. Fortunately, significant efforts are already being directed to alleviate this limitation. Some groups have had success inducing formation of primitive blood vessel-like structures through vascular endothelial growth factor (VEGF) treatment during organoid formation [50]. Other successful attempts utilized organoids formed from human embryonic stem cells (hESCs) engineered to ectopically express ETV2 [51], or a co-culture of organoids and endothelial cells [52]. The potential of these structures to model important interactions between GBM and the perivascular niche represent exciting opportunities to expand the scope of this emerging model system down a number of increasingly more complex avenues. However, as vascularized organoids have yet to be used in GBM modeling, the ability of these structures to successfully model such interactions has yet to be seen.

Another important limitation, when compared to in vivo counterparts, is the lack of microglia or other critical immune cells in organoid-based models of GBM. The presence of microglia has been shown in cerebral organoids generated through certain protocols and can likely be further optimized to increase enrichment for these cells [53]. However, this approach relies on the generation of mesoderm progenitors within the cerebral organoid, which may give rise to other mesoderm-derived, non-neuronal tissues and compromise existing advantages. Additionally, in its current state, the quantity of microglia in organoids generated by this method, varies significantly which could further exacerbate the existing issue of inter-organoid heterogeneity. Whether this approach can be successfully integrated into organoid models of GBM while maintaining sufficient inter-organoid consistency remains an open question. Recent complementary efforts have attempted to bypass this issue by separately differentiating microglia-like cells and subsequently co-culturing them with isogenic, brain-region specific organoids. Initial results from these approaches, have been encouraging and appear to support that such exogenous production of microglia does not compromise functional interactions between them and other neuronal cell types within the organoids [54]. Analogous approaches could take advantage of well-established protocols for induced pluripotent stem cell (iPSC)-derived microglia in efforts to recapitulate the immune microenvironment [55, 56]. Similarly to the case of microglia, other reports also describe protocols for the generation of additional immune cell types from stem cells, such as monocytes and macrophages [57], T lymphocytes [58] and granulocytes [59]. Whether these immune components can be consistently and successfully incorporated into cerebral organoids without affecting established neuronal activities and interactions within the organoids remains to be investigated. If such incorporation efforts are successful, the prospects of introducing these additional immune components to the tumor immune microenvironment in the hybrid GBM-cerebral organoid model could further fuel interest in this advanced hybrid system. These are exciting areas of future developments, as they would foster development of scalable models for the pre-clinical and robust testing of emerging novel or immunotherapy treatments. A recent study reported the treatment of GBM-derived organoids with EGFRvIII-specific CAR-T cells that successfully induced cell death, EGFRvIII antigen loss and T cell activation only in those organoids deriving from GBM samples with high expression of EGFRvIII, a commonly mutated variant in glioblastoma [21]. Even though these three-dimensional structures were wholly derived from GBM, the successful and functional interaction between them and the CAR-T cell treatment points towards an increased likelihood that the hybrid system will also be successfully utilized in similar investigations.

As discussed, there is a strong potential for the use of these hybrid organoid models in many areas ranging from basic research to clinical investigations. Of therapeutic interest, there are important prospects in the use of hybrid cerebral organoid/GBM systems as a platform for drug screening, including for targeting tumor invasion and therapy-resistant populations of glioma cells. Initial proof-of-principle experiments where these models were treated with well-established chemotherapy drugs [31, 36] show promise in their utility to assess drug efficacies in controlling invasion and growth of GBM within them. Therapy-resistant populations of GBM have also been tested with temozolomide in GBM-derived organoids [60]. Whether these GBM subpopulations will be successfully integrated in the hybrid model remains to be seen. Besides the aforementioned efforts, organoid systems have been significantly leveraged in drug screening studies whether for the purpose of elucidating mechanisms of synergistic toxicity in medulloblastoma models [61] or in the context of neurodegeneration [62, 63] and epilepsy [64, 65]. Adding more layers of cellular complexity is expected to improve accuracy and efficient modelling of disease. Another exciting possibility is utilizing patient-derived tumor samples and iPSCs derived from the same individual to generate patient-specific tumor avatars for personalized drug testing. There is also the potential for patient iPSC collection to occur concurrently with existing tumor organoid biobanking efforts [21]. This would enable researchers to generate large repositories of tumor and patient-matched cerebral organoids that could be used in comparisons between tumor and healthy tissue as well as tumor invasion studies. Such efforts would also enable concurrent testing of both drug efficacy and toxicity in genetically matched samples.

Up to now, published studies have had outputs focused on the genomic or transcriptional level of these new hybrid cell systems and have been successful in showing how they are distinctly different from earlier in vitro cultures of GBM. Importantly, studies have also shown that the profiles of GBM cells grown within such a system are closer to the molecular profiles of GBM cells isolated from primary tissue than to earlier culture protocols. Therefore, extending the outputs of this new model to other-omics technologies, such as proteomics and epigenomics, seems the natural step that could combine with functional studies to provide concrete candidates for therapeutics. Medium throughput chemical or CRISPR-based screens can also be leveraged towards the same goal. To this end, further optimizations such as the integration of tissue clearing and quantitative 3D imaging will likely continue to increase the potential throughput of this system [66]. Whether any novel candidates or insights that might come out from these efforts will prove effective in slowing the progression of the disease in the clinic remains to be seen. If successful, this approach can potentially be expanded to other cancers with poor outcomes in need of an alternative path to generate new and meaningful therapies. Table 1 below summarizes the different approaches for the generation of this novel ex vivo model along with their strengths and weaknesses and corresponding references.

Table 1 Summary of the different ex vivo models of GBM


The lack of significant improvement in GBM outcomes over recent decades spanning numerous breakthroughs in our understanding of the cellular and molecular mechanisms of cancer supports the continued search for alternative approaches to model and study this aggressive disease in the laboratory. Here we review the evolution and use of well-established stem cell protocols to generate tridimensional neuronal tissue with a cellular diversity similar to the human brain, particularly in the form of cerebral organoids. These dynamic cell aggregates are highly amenable to a wide array of experimental manipulations, including their ability to fuse with GSCs or engender a GBM-like cellular phenotype through genetic engineering. Initial studies have validated the distinct nature of these models and established them as a valuable and faithful platform for functional, multi-omic and drug screening initiatives. These hold significant potential for uncovering the underlying mechanisms of central features of GBM, such as infiltration and hypoxia. They also provide advanced systems for drug screening and the nomination of new targets for therapeutic efforts. In light of the highly plastic nature of GBM cells and the importance of the interactions within the tumor microenvironment [67], recent and upcoming research using these new models appears to constitute a promising approach. Continued use and further development of these advanced systems can potentially garner important progress and ultimately concrete improvements in the management of patients with glioblastoma.

Availability of data and materials

Not applicable.



Central nervous system


Cerebral organoid


COUP-TF-interacting protein 2






Extracellular matrix


Epidermal growth factor receptor


ETS variant transcription factor 2


Glioblastoma multiforme


Glial fibrillary acidic protein


Green fluorescent protein


Glioma cerebral organoid


Glioblastoma stem cell


Human embryonic stem cell


Human pluripotent stem cell

HRasG12V :

Mutant HRas where glycine is replaced by valine at position 12


Induced pluripotent stem cell


Patient-derived xenograft


Protein Tyrosine Phosphatase Receptor Type Z1


SRY-Box Transcription Factor 2


Tumor protein 53


Vascular endothelial growth factor


  1. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE et al (2014) The epidemiology of glioma in adults: a state of the science review. Neuro Oncol 16:896–913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Delgado-López PD, Corrales-García EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18:1062–1071.

    Article  CAS  PubMed  Google Scholar 

  3. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522–526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G et al (2006) Chemotherapy resistance of glioblastoma stem cells [2]. Cell Death Differ 13:1238–1241.

    Article  CAS  PubMed  Google Scholar 

  5. Paolillo M, Boselli C, Schinelli S (2018) Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci 8:15.

    Article  CAS  PubMed Central  Google Scholar 

  6. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma (Cancer Research (October 2004) 64 (7011-7021). Cancer Res 64:8130

    Article  CAS  Google Scholar 

  7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401.

    Article  CAS  PubMed  Google Scholar 

  8. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568–580.

    Article  CAS  PubMed  Google Scholar 

  9. Zanders ED, Svensson F, Bailey DS (2019) Therapy for glioblastoma: is it working? Drug Discov Today 24:1193–1201.

    Article  PubMed  Google Scholar 

  10. Monje M, Borniger JC, D’Silva NJ, Deneen B, Dirks PB, Fattahi F et al (2020) Roadmap for the emerging field of cancer neuroscience. Cell 181:219–222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T et al (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573:532–538.

    Article  CAS  PubMed  Google Scholar 

  12. Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M et al (2019) Electrical and synaptic integration of glioma into neural circuits. Nature 573:539–545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schuhmacher AJ, Squatrito M (2017) Animal models in glioblastoma: use in biology and developing therapeutic strategies. In: Somasundaram K (ed) Advances in biology and treatment of glioblastoma. Current Cancer Research. Springer, Cham, pp 219–240.

    Chapter  Google Scholar 

  14. Lui JH, Hansen DV, Kriegstein AR (2011) Development and evolution of the human neocortex. Cell 146:18–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hackam DG, Redelmeier DA (2006) Translation of research evidence from animals to humans. JAMA 296:1727.

    Article  Google Scholar 

  16. Shanks N, Greek R, Greek J (2009) Are animal models predictive for humans? Philos Ethics Humanit Med 4:1–20.

    Article  Google Scholar 

  17. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V et al (2010) Can animal models of disease reliably inform human studies? PLoS Med 7:e1000245.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J et al (2017) Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 49:1567–1575.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Herrera-Perez M, Voytik-Harbin SL, Rickus JL (2015) Extracellular matrix properties regulate the migratory response of glioblastoma stem cells in three-dimensional culture. Tissue Eng Part A 21:2572–2582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC et al (2016) A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res 76:2465–2477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH et al (2020) A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180:188–204.e22.

    Article  CAS  PubMed  Google Scholar 

  22. Nayernia Z, Turchi L, Cosset E, Peterson H, Dutoit V, Dietrich PY et al (2013) The relationship between brain tumor cell invasion of engineered neural tissues and invivo features of glioblastoma. Biomaterials 34:8279–8290.

    Article  CAS  PubMed  Google Scholar 

  23. Plummer S, Wallace S, Ball G, Lloyd R, Schiapparelli P, Quiñones-Hinojosa A et al (2019) A human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Sci Rep 9:1–11.

    Article  CAS  Google Scholar 

  24. Pamies D, Barreras P, Block K, Makri G, Kumar A, Wiersma D et al (2017) A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. ALTEX 34:362–376.

    Article  PubMed  Google Scholar 

  25. Quadrato G, Nguyen T, Macosko EZ, Sherwood JL, Yang SM, Berger DR et al (2017) Cell diversity and network dynamics in photosensitive human brain organoids. Nature 545:48–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Velasco S, Kedaigle AJ, Simmons SK, Nash A, Rocha M, Quadrato G et al (2019) Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature 570:523–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lancaster MA, Corsini NS, Wolfinger S, Gustafson EH, Phillips AW, Burkard TR et al (2017) Guided self-organization and cortical plate formation in human brain organoids. Nat Biotechnol 35:659–666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li Y, Muffat J, Omer A, Bosch I, Lancaster MA, Sur M et al (2017) Induction of expansion and folding in human cerebral organoids. Cell Stem Cell 20:385–396.e3.

    Article  CAS  PubMed  Google Scholar 

  29. Pellegrini L, Bonfio C, Chadwick J, Begum F, Skehel M, Lancaster MA (2020) Human CNS barrier-forming organoids with cerebrospinal fluid production. Science (80-) 5626:eaaz5626.

    Article  CAS  Google Scholar 

  30. Qian X, Song H, Ming GL (2019) Brain organoids: advances, applications and challenges. Dev.

    Article  Google Scholar 

  31. Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA et al (2018) Genetically engineered cerebral organoids model brain tumor formation. Nat Methods 15:631–639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ogawa J, Pao GM, Shokhirev MN, Verma IM (2018) Glioblastoma model using human cerebral organoids. Cell Rep 23:1220–1229.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ortensi B, Setti M, Osti D, Pelicci G (2013) Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther 4:1–11.

    Article  CAS  Google Scholar 

  34. Bhaduri A, Di Lullo E, Jung D, Müller S, Crouch EE, Espinosa CS et al (2020) Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell 26:48–63.e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Krieger TG, Tirier SM, Park J, Jechow K, Eisemann T, Peterziel H et al (2020) Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics. Neuro Oncol.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T et al (2019) Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep 26:3203–3211.e5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pine AR, Cirigliano SM, Nicholson JG, Hu Y, Linkous A, Miyaguchi K et al (2020) Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas. Cancer Discov.

    Article  PubMed  Google Scholar 

  38. da Silva B, Mathew RK, Polson ES, Williams J, Wurdak H (2018) Spontaneous glioblastoma spheroid infiltration of early-stage cerebral organoids models brain tumor invasion. SLAS Discov 23:862–868.

    Article  CAS  PubMed  Google Scholar 

  39. Bagley JA, Reumann D, Bian S, Lévi-Strauss J, Knoblich JA (2017) Fused cerebral organoids model interactions between brain regions. Nat Methods 14:743–751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hodge RD, Bakken TE, Miller JA, Smith KA, Barkan ER, Graybuck LT et al (2019) Conserved cell types with divergent features in human versus mouse cortex. Nature 573:61–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J et al (2015) Brain tumour cells interconnect to a functional and resistant network. Nature 528:93–98.

    Article  CAS  PubMed  Google Scholar 

  42. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068.

    Article  CAS  Google Scholar 

  43. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kratochvil MJ, Seymour AJ, Li TL, Paşca SP, Kuo CJ, Heilshorn SC (2019) Engineered materials for organoid systems. Nat Rev Mater 4:606–622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yoon SJ, Elahi LS, Pașca AM, Marton RM, Gordon A, Revah O et al (2019) Reliability of human cortical organoid generation. Nat Methods 16:75–78.

    Article  CAS  PubMed  Google Scholar 

  46. Jacob F, Pather SR, Huang WK, Zhang F, Wong SZH, Zhou H et al (2020) Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell 27:1–14.

    Article  CAS  Google Scholar 

  47. Sivitilli AA, Gosio JT, Ghoshal B, Evstratova A, Trcka D, Ghiasi P et al (2020) Robust production of uniform human cerebral organoids from pluripotent stem cells. Life Sci Alliance 3:1–10.

    Article  Google Scholar 

  48. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P (2006) Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 53:799–808.

    Article  PubMed  Google Scholar 

  49. Infanger DW, Cho YJ, Lopez BS, Mohanan S, Liu SC, Gursel D et al (2013) Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res 73:7079–7089.

    Article  CAS  PubMed  Google Scholar 

  50. Ham O, Jin YB, Kim J, Lee MO (2020) Blood vessel formation in cerebral organoids formed from human embryonic stem cells. Biochem Biophys Res Commun 521:84–90.

    Article  CAS  PubMed  Google Scholar 

  51. Cakir B, Xiang Y, Tanaka Y, Kural MH, Parent M, Kang YJ et al (2019) Engineering of human brain organoids with a functional vascular-like system. Nat Methods 16:1169–1175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Pham MT, Pollock KM, Rose MD, Cary WA, Stewart HR, Zhou P et al (2018) Generation of human vascularized brain organoids. Neuroreport 29:588–593.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Ormel PR, Vieira de Sá R, van Bodegraven EJ, Karst H, Harschnitz O, Sneeboer MAM et al (2018) Microglia innately develop within cerebral organoids. Nat Commun.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Song L, Yuan X, Jones Z, Vied C, Miao Y, Marzano M et al (2019) Functionalization of brain region-specific spheroids with isogenic microglia-like cells. Sci Rep 9:1–18.

    Article  CAS  Google Scholar 

  55. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA et al (2017) iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94:278–293.e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S et al (2016) Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med 22:1358–1367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cao X, Yakala GK, van den Hil FE, Cochrane A, Mummery CL, Orlova VV (2019) Differentiation and functional comparison of monocytes and macrophages from hiPSCs with peripheral blood derivatives. Stem Cell Rep 12:1282–1297.

    Article  CAS  Google Scholar 

  58. Montel-Hagen A, Seet CS, Li S, Chick B, Zhu Y, Chang P et al (2019) Organoid-induced differentiation of conventional T cells from human pluripotent stem cells. Cell Stem Cell 24:376–389.e8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C et al (2015) Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Rep 4:282–296.

    Article  CAS  Google Scholar 

  60. Tejero R, Huang Y, Katsyv I, Kluge M, Lin JY, Tome-Garcia J et al (2019) Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine 42:252–269.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Frisira E, Rashid F, Varma SN, Badodi S, Benjamin-Ombo VA, Michod D et al (2019) NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma. Cell Death Dis.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ghatak S, Dolatabadi N, Gao R, Wu Y, Scott H, Trudler D et al (2020) NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Mol Psychiatry.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Grenier K, Kao J, Diamandis P (2020) Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. Mol Psychiatry 25:254–274.

    Article  PubMed  Google Scholar 

  64. Bershteyn M, Nowakowski TJ, Pollen AA, Di Lullo E, Nene A, Wynshaw-Boris A et al (2017) Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. Cell Stem Cell 20:435–449.e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Iefremova V, Manikakis G, Krefft O, Jabali A, Weynans K, Wilkens R et al (2017) An organoid-based model of cortical development identifies non-cell-autonomous defects in Wnt signaling contributing to miller-dieker syndrome. Cell Rep 19:50–59.

    Article  CAS  PubMed  Google Scholar 

  66. Goranci-Buzhala G, Mariappan A, Gabriel E, Ramani A, Ricci-Vitiani L, Buccarelli M et al (2020) Rapid and efficient invasion assay of glioblastoma in human brain organoids. Cell Rep 31:107738.

    Article  CAS  PubMed  Google Scholar 

  67. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ et al (2019) An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178:835–849.e21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


The Diamandis laboratory is supported through grants from the Ontario Institute for Cancer Research (Ontario Molecular Pathology Research Network), the Terry Fox Research Foundation New Investigator Awards Program and the Princess Margaret Cancer Foundation.

Author information

Authors and Affiliations



All authors contributed equally. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Phedias Diamandis.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papaioannou, MD., Sangster, K., Sajid, R.S. et al. Cerebral organoids: emerging ex vivo humanoid models of glioblastoma. acta neuropathol commun 8, 209 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: